Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China

Petrochina Company Limited

North China Electric Power University

Beijing New Building Materials Public Limited Company

Hongxia Chen

Yunfeng Li

Rui Xue

Wei Wang

Peng Li

Fan Li

Nan Zhao

Youzhi Zhang

Cheng Zhang

Ning Zhang

Jingyuan Zhang

Qian Chen

Yanping Zhang

Xia Wang

Liuhong Yun

Bohua Zhong

Sihan Wang

Rifang Yang

Yongjun Zhang

Xinhua He

Guizhi Wang

Rusheng Zhao

Baojun Zhang

Jianzhong Li

Shukun Sun

Deshun Zhang

Huimin Yuan

Jinliang Xu

Yongzhen Li

Juanjuan Qin

Yunguang Han

Li Yuan

Yulong Li

Zhenzhen Wang

Yongcheng Sun

Meiying Li

Yingnan Ning

Dongting Kuang

Lihua Xing

Jiazhi Yao

Xiaodan Xu

Zengliang Jin

Fenghua Bai

Fade Wu

Mengwen Zhou

Xiaofei Zhang

Jianzhong Zhou

Xiuyun Ran

Zengling Jin

An internal liquid separating hood-type condensation head exchange tube, comprising an external heat exchange tube and an internal liquid separating hood disposed in the cavity of the external heat exchange tube and coaxial with the external heat exchange tube. The internal liquid separating hood is a hollow tube with a plurality of micropores or gaps distributed on a wall surface. The condensate formed during the heat exchange is pumped to the internal liquid separating hood in time under the effect of surface tension of the liquid via the micropores or gaps, and then is discharged from the heat exchange tube by the internal liquid separating hood. Vapor is retained to flow in the annular region between the external heat exchange tube and the internal liquid separating hood, so the inner wall of the external heat exchange tube comes into contact with the vapor to the greatest extent.

Internal liquid separating hood-type condensation heat exchange tube

Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof.  The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.

1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof

The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R, Rand n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable salt for the manufacture of an anti-depressent drug. 

Amine compounds and medical uses thereof

The present invention relates to a catalyst composition for ethylene oligomerization and the use thereof. Such catalyst composition includes chromium compound, ligand containing P and N, activator and accelerator; wherein the chromium compound is selected from the group consisting of acetyl acetone chromium, THF-chromium chloride and Cr(2-ethylhecanoate); general formula of the ligand containing P and N is shown as: in which R, R, Rand Rare phenyl, benzyl, or naphthyl. Ris isopropyl, butyl, cyclopropyl, cyclopentyl, cyclohexyl or fluorenyl; the activatior is methyl aluminoxane, ethyl aluminoxane, propyl aluminoxane and/or butyl aluminoxane; the accelerator is selected from the group consisting of 1,1,2,2,-tetrachloroethane, 1,1,2,2-tetrabromoethane, 1,1,2,2-tetrafluoroethane, and compounds having a formula of XRX, in which Xand Xare F, Cl, Br, I or alkoxyl, Ris alkylene or arylene group; the molar ratio of chromium compound, ligand containing P and N, activator and accelerator is 1:0.5&#x2dc;10:50&#x2dc;3000:0.5&#x2dc;10. After mixing the four components mentioned previously under nitrogen atmosphere for 10 minutes, they are incorporated to the reactor, or these four components are incorporated directly into the reactor. Then ethylene is introduced for oligomerization. Such catalyst can be used in producing 1-octene through ethylene oligomerization. It is advantageous in high catalysing activity, high 1-octene selectivity, etc. The catalytic activity is more than 1.0&#xd7;10g product&#xb7;maCr&#xb7;h, the fraction of Clinear &#x3b1;-olefin is more than 70% by mass.

Catalyst composition for ethylene oligomerization and the use thereof

Growing community of inventors

Beijing, China

Hongxia Chen